Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sacubitril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME known ✓ | P08473 | 13/20 | 0.77 |
| ▸ | ACE | P12821 | 4/20 | 0.77 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sacubitril SCHEMBL1908525 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL489040 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL22420467 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL8214132 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL18574632 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL18059569 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL18059568 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL21239958 | 0.99 | MME (0.76) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL21239955 | 0.99 | MME (0.76) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL17746036 | 0.99 | MME (0.76) | MMEACEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1887 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103833-A1 | PHARMACEUTICAL COMPOSITION OF ARNI AND BISOPROLOL OR SALT THEREOF, AND USE THEREOF | 深圳信立泰药业股份有限公司 | 2026-05-21 | — | — | WO | claimed |
| US-20260115166-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PHOTORECEPTOR ROD DEGENERATIONS AND GENERATION OF PHOTORECEPTORS | PURDUE RESEARCH FOUNDATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-3934654-B1 | ISTAROXIME OR ITS METABOLITE PST-3093 FOR USE AS INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS INC (US) | 2026-04-29 | — | — | EP | claimed |
| US-12613248-B2 | Full-length CILP as a biomarker for cardiac fibrosis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-28 | — | — | US | claimed |
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | claimed |
| US-12582601-B2 | Orodispersible powder composition | BIOPHARMA SYNERGIES, S.L. (ES) | 2026-03-24 | — | — | US | claimed |
| EP-4694856-A1 | CALENDAR MEDICATION BLISTER PACK, METHOD OF USING THEREOF AND ELECTRONIC SYSTEM OF MANAGEMENT OF INTERACTION WITH CALENDAR MEDICATION BLISTER PACK | Mili Healthcare Trade Fzco (AE) | 2026-02-18 | — | — | EP | claimed |
| US-12521402-B2 | Biomarker and drug combinations for heart failure prediction | Endothelium Scanning Nanotechnology Limited (AU) | 2026-01-13 | — | — | US | claimed |
| US-20260000679-A9 | BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION | ENDOTHELIUM SCANNING NANOTECHNOLOGY LTD (AU) | 2026-01-01 | — | — | US | claimed |
| US-12508246-B2 | Uses of complex of angiotensin II receptor antagonist metabolite and NEP inhibitor in treating heart failure | SHENZHEN SALUBRIS PHARMACEUTICALS CO. LTD. (CN) | 2025-12-30 | — | — | US | claimed |
| WO-2015030711-A1 | NEW USE | NOVARTIS AG (CH) | 2015-03-05 | — | — | WO | claimed |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2014-11-13 | — | — | US | claimed |
| US-20140329872-A1 | TREATMENT OF HYPERTENSION AND/OR PREVENTION OR TREATMENT OF HEART FAILURE IN A MAMMAL RECEIVING ANTI-COAGULANT THERAPY | NOVARTIS AG (CH) | 2014-11-06 | — | — | US | claimed |
| EP-1948158-B1 | PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | claimed |
| EP-2640375-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | Novartis AG (CH) | 2013-09-25 | — | — | EP | claimed |
| EP-2608784-A1 | TREATMENT OF HYPERTENSION AND/OR PREVENTION OR TREATMENT OF HEART FAILURE IN A MAMMAL RECEIVING ANTI-COAGULANT THERAPY | Novartis AG (CH) | 2013-07-03 | — | — | EP | claimed |
| US-20130158088-A1 | TREATMENT OF HYPERTENSION AND/OR PREVENTION OR TREATMENT OF HEART FAILURE IN A MAMMAL RECEIVING ANTI-COAGULANT THERAPY | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | claimed |
| WO-2012065958-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | claimed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | claimed |
| WO-2012027237-A1 | TREATMENT OF HYPERTENSION AND/OR PREVENTION OR TREATMENT OF HEART FAILURE IN A MAMMAL RECEIVING ANTI-COAGULANT THERAPY | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000679-A9 | BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION | NPPA, TNNT2, SLC5A2 | MME 52/4885ACE 85/4885MMEL1 340/4885 |
| US-12508246-B2 | Uses of complex of angiotensin II receptor antagonist metabolite and NEP inhibitor in treating heart failure | AGTR2, AGTR1, MME | MME 3/4885ACE 6/4885MMEL1 575/4885 |
| US-20260115166-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PHOTORECEPTOR ROD DEGENERATIONS AND GENERATION OF PHOTORECEPTORS | ADRB3, ADRB2, ARRB1 | MME 1251/4885ACE 1235/4885MMEL1 3454/4885 |
| US-12613248-B2 | Full-length CILP as a biomarker for cardiac fibrosis | COL2A1, TGFB1, FABP3 | MME 90/4885ACE 80/4885MMEL1 173/4885 |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | MME 3/4885ACE 92/4885MMEL1 118/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | MME 3/4885ACE 92/4885MMEL1 118/4885 |
| US-12582601-B2 | Orodispersible powder composition | OTC, SORD, OAT | MME 1501/4885ACE 96/4885MMEL1 4069/4885 |
| US-12605384-B2 | Uses | PDE2A, NPR1, PDE7A | MME 2037/4885ACE 640/4885MMEL1 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.